Anika Therapeutics, Inc 8-K, filed Nov 6, 2026
Anika Therapeutics, Inc. (ANIK)
About this 8-K
Anika Therapeutics, Inc filed this 8-K on November 6, 2026.
Anika Therapeutics reported third-quarter revenue of $30.6 million, up 10% year over year, raised 2026 revenue guidance to 6% to 10% and adjusted EBITDA margin guidance to 15% to 17%, while receiving FDA notice that Hyalofast PMA application was not approvable. AI summary
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
On November 6, 2026, Anika Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 | Press Release of Anika Therapeutics, Inc. dated November 6, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Anika Therapeutics, Inc. | ||
| Date: November 6, 2026 | By: | /s/ Stephen Griffin |
| Stephen Griffin | ||
| President and Chief Executive Officer | ||
EXHIBIT 99.1
Anika Reports Third Quarter 2026 Financial Results
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue
Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product
Raised Lower End of Full-Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance
BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.
Total revenue for the third quarter was $30.6 million, compared with $27.8 million in the prior-year period, representing 10% year over year growth. Performance was driven by continued Commercial Channel growth and steady Original Equipment Manufacturer (OEM) Channel execution, with Commercial Channel revenue of $14.0 million, up approximately 17% year over year, and OEM Channel revenue of $16.6 million, up approximately 5% year over year.
Third quarter results reflected continued progress on Anika’s strategy to accelerate revenue growth, strengthen operations and advance the pipeline. International viscosupplement revenue increased 19% year over year, total Regenerative Solutions revenue increased 12%, and Integrity revenue grew both sequentially and by more than 30% year over year despite more market-wide seasonality than usual in the summer months. Strong Integrity performance was supported in part by the larger implant sizes introduced in the fourth quarter of 2025 and first quarter of 2026, respectively, which expanded use into other tendon applications including foot & ankle and knee.
“Through the first nine months of 2026, we have executed against the three priorities we established at the start of the year: accelerating revenue growth, strengthening operational execution and advancing our pipeline. We delivered double-digit year to date revenue growth across both channels, secured a long-term agreement that improves the durability and economics of an important commercial relationship, increased manufacturing capacity to support future growth, fully enrolled the Cingal bioequivalence study and expanded Integrity adoption,” said Steve Griffin, President and Chief Executive Officer. “Third quarter results reflect the continued execution against these priorities and represent key milestones to improve durable growth and drive sustained profitability. Taken together, this progress reinforces our confidence in our full-year 2026 outlook and our 2027 revenue expectations.”
Accelerating Revenue Growth
Anika delivered a solid third quarter, highlighted by growth across both channels and continued progress on key pipeline and operational priorities. Through the first nine months, Anika has delivered double-digit revenue growth in both channels, with Commercial Channel revenue increasing 15% and OEM Channel revenue increasing 11% year to date. As part of the Company’s strategy to drive sustainable long-term growth, an enhanced long-term commercial agreement with improved economics has been secured increasing revenue visibility and unlocking additional value in one of our non-orthopedic product franchises.
Strengthening Operational Discipline
Operational discipline remains central to Anika’s value creation strategy. Gross margin improved meaningfully year over year driven by manufacturing productivity offset partially by product mix from the reintroduction of Hyalomatrix®, a Hyaff wound product. Anika continues to improve manufacturing execution through stronger production planning, process improvements and sourcing flexibility, including FDA approval of new aseptic manufacturing processes and validation of a second cross-link filler. Because demand has exceeded forecasts, the Company has significantly increased throughput. Unit volumes on Anika’s cross-link line are now more than 50% above 2022 levels, and further opportunity exists to expand output. As demand continues to grow, the Company is increasing production and building safety stock to support future growth, which is expected to drive additional productivity gains and gross margin improvement over time.
Advancing the Pipeline
In September, enrollment in the Cingal bioequivalence study was completed. Following completion of the clinical study report and chemistry, manufacturing and controls (CMC) work required to file HA as a drug, Anika expects the Cingal new drug application (NDA) to be submitted before year-end 2027.
In October, the Company received formal notification from the FDA that the Hyalofast® pre-market approval (PMA) application is not approvable, primarily based on the clinical data included in the submission. Anika continues to believe strongly in Hyalofast’s potential in the U.S. market and is continuing to assess the available regulatory pathways and next steps, including discussions with the FDA regarding the additional evidence that may be required to support a future approval.
Third Quarter 2026 Business Highlights and Updates
- Total third quarter revenue was $30.6 million, up 10% year over year, reflecting continued execution across Commercial and OEM Channels.
- Commercial Channel revenue increased 17% year over year to $14.0 million, supported by international viscosupplement growth and Integrity adoption.
- International OA Pain Management revenue increased 19% year over year in the third quarter and 16% year to date, reflecting sustained strong demand on both Cingal and Monovisc.
- OEM Channel revenue increased 5% year over year in the third quarter, supported by Hyvisc growth and J&J DePuy Synthes sales.
- In November, Anika entered a new 10-year partnership for the distribution of Hyvisc with its existing partner, Boehringer Ingelheim. The agreement provides higher transfer pricing, a royalty on end-market sales, higher contractual purchases and upfront and milestone payments. In total, we expect to receive $8 million in payments, including a $4 million upfront payment in the first quarter of 2027 and remaining $4 million tied to commercial volumes.
- Integrity revenue recorded sequential growth and increased more than 30% year over year in the third quarter despite a slower than anticipated third quarter elective surgery market. Despite these market dynamics, Integrity contributed $7.5 million in revenue for the trailing 12 months. Strong performance was supported in part by the larger sizes introduced in the fourth quarter of 2025 and first quarter of 2026 which expanded use into other tendon applications including foot & ankle and knee. Integrity revenue has increased 37% year to date. Commercial Channel Revenue 2026 guidance has been updated to reflect this slower elective surgery market.
- Anika’s second-generation Integrity instrumentation launched in September, providing surgeons with an alternative insertion and deployment option designed to support differences in surgeon preference.
- In October, Anika received formal notification from the U.S. Food and Drug Administration (FDA) that its Hyalofast PMA application is not approvable, primarily based on the clinical data included in the submission. Anika continues to believe strongly in Hyalofast’s potential in the U.S. market and is assessing available regulatory pathways and next steps.
- Cingal bioequivalence study enrollment was completed in September, CMC preparation is progressing, and Anika expects an NDA submission before year-end 2027.
- Anika reintroduced Hyalomatrix, a Hyaff wound product, in the U.S. through a new OEM distributor with first commercial units shipped during the third quarter.
Third Quarter 2026 Continuing Operations Financial Summary
- Revenue: $30.6 million, up 10% year over year
- Commercial Channel revenue: $14.0 million, up 17%
- OEM Channel revenue: $16.6 million, up 5%
- Gross margin: 62%, compared with 56% in the prior-year period
- Operating expenses: $19.5 million, up 4% year over year
- GAAP loss from continuing operations: $0.3 million, or $0.02 per diluted share
- Adjusted net income from continuing operationsˆ: $3.9 million, or $0.29 per diluted share
- Adjusted EBITDAˆ: $5.1 million
- Cash and cash equivalents: $45.0 million as of September 30, 2026
ˆSee description of non-GAAP financial information contained in this release.
Fiscal 2026 and 2027 Guidance
Anika is raising the lower end of its full-year 2026 total company revenue guidance, reaffirming its full-year 2027 total company revenue guidance and raising full-year 2026 adjusted EBITDA guidance. The Company is updating its 2026 channel revenue guidance to reflect a greater contribution from the OEM Channel and more measured Commercial Channel growth.
2026 Guidance
- Total Company revenue growth: 6% to 10%, compared to 5% to 10% previously
- OEM Channel revenue growth: 5% to 9%, compared to 0% to 5% previously
- Commercial Channel revenue growth: 9% to 13%, compared to 12% to 18% previously
- Adjusted EBITDA margin: 15% to 17%, compared to 13% to 17% previously
2027 Revenue Guidance
- Total Company revenue growth: Flat to 5%
- OEM Channel revenue growth: Flat to modestly lower
- Commercial Channel revenue growth: 5% to 15%
Conference Call and Webcast Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights on November 6, 2026, at 8:30 am ET. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 27870. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our primary focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, HYVISC, HYALOMATRIX, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
Non-GAAP Financial Information1
Non-GAAP financial measures should be considered supplemental to, and not a substitute for, Anika’s reported financial results prepared in accordance with GAAP. Furthermore, Anika’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease Anika’s reported results of operations, Anika strongly encourages investors to review Anika’s consolidated financial statements and publicly filed reports in their entirety. Anika presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing its operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. Anika also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.
Adjusted EBITDA
Adjusted EBITDA is defined by Anika as GAAP net loss from continuing operations excluding depreciation and amortization, interest and other income (expense), net, income taxes, stock-based compensation expense, non-recurring professional fees and severance costs.
Adjusted Net Income (Loss) from Continuing Operations and Adjusted Earnings Per Share (“EPS”) from Continuing Operations
Adjusted net income (loss) from continuing operations is defined by Anika as GAAP net income (loss) from continuing operations, on a tax effected basis, excluding stock-based compensation, non-recurring professional fees and severance costs. Adjusted diluted EPS from continuing operations is defined by Anika as GAAP diluted EPS from continuing operations excluding stock-based compensation, non-recurring professional fees and severance costs, each on a tax effected and per share basis.
A reconciliation of adjusted EBITDA to adjusted net income (loss) from continuing operations to net income (loss) from continuing operations and adjusted diluted EPS from continuing operations to diluted EPS from continuing operations, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.
Anika has not provided a reconciliation of its forward-looking adjusted EBITDA margin guidance to the most directly comparable GAAP financial measure because it is unable to predict with reasonable certainty the occurrence or amount of items such as stock-based compensation expense, severance costs, non-recurring professional fees and certain other items that may affect GAAP results. The effect of these items could be material, and therefore a reconciliation is not available without unreasonable effort.
Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning Anika’s expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including express or implied statements regarding Anika’s 2026 revenue and adjusted EBITDA guidance, and 2027 revenue guidance; Anika’s product development activities, including clinical trials, regulatory submissions and reviews, including for Cingal and Hyalofast;, manufacturing improvements and capacity expansion; receipt of milestone payments and royalties; margin contributions from product reintroductions; and other, operational initiatives and pipeline advancement, among others. These express or implied statements are based upon the current beliefs and expectations of Anika’s management and are subject to significant risks, uncertainties, and other factors. Anika's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, risks related to (i) Anika’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) Anika’s ability to obtain pre-clinical or clinical data to support regulatory approvals; (iii) other regulatory, commercial, and operational risks, including related to manufacturing, production planning, addressing customer demands and supply chain risks ; (iv)achieving success from its research and product development efforts, including any future product sales; (v) the cost effectiveness and efficiency of its manufacturing operations and production planning; (vi) the strength of the economies in which Anika operates or will be operating, as well as political stability in such geographies; (vii) future resource allocation determinations; (viii) achieving growth targets and realizing expected economic benefits; (ix) receipt of milestone payments and royalties under its distribution agreements, including the recently renewed Boehringer Ingelheim agreement; and (x) achieving anticipated margin contributions and commercial returns from product reintroductions and new product launches. Additional factors and risks are described in Anika’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available on the date of this press release, and Anika assumes no obligation to update the information contained in this press release.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
investorrelations@anika.com
| Anika Therapeutics, Inc. and Subsidiaries | ||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | $ | 30,594 | $ | 27,817 | $ | 92,816 | $ | 82,204 | ||||||||
| Cost of revenue | 11,757 | 12,233 | 33,738 | 37,576 | ||||||||||||
| Gross profit | 18,837 | 15,584 | 59,078 | 44,628 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 7,895 | 6,946 | 21,949 | 19,318 | ||||||||||||
| Selling, general and administrative | 11,654 | 11,871 | 40,375 | 37,007 | ||||||||||||
| Total operating expenses | 19,549 | 18,817 | 62,324 | 56,325 | ||||||||||||
| Loss from operations | (712 | ) | (3,233 | ) | (3,246 | ) | (11,697 | ) | ||||||||
| Interest and other income (expense), net | 390 | 997 | 1,483 | 1,626 | ||||||||||||
| Loss before income taxes | (322 | ) | (2,236 | ) | (1,763 | ) | (10,071 | ) | ||||||||
| (Benefit from) provision for income taxes | (11 | ) | 939 | 295 | 1,709 | |||||||||||
| Loss from continuing operations | (311 | ) | (3,175 | ) | (2,058 | ) | (11,780 | ) | ||||||||
| Income from discontinued operations, net of tax | - | 846 | - | 608 | ||||||||||||
| Net loss | $ | (311 | ) | $ | (2,329 | ) | $ | (2,058 | ) | $ | (11,172 | ) | ||||
| Net income (loss) per share: | ||||||||||||||||
| Basic | ||||||||||||||||
| Continuing Operations | $ | (0.02 | ) | $ | (0.22 | ) | $ | (0.15 | ) | $ | (0.82 | ) | ||||
| Discontinued Operations | $ | - | $ | 0.06 | $ | - | $ | 0.04 | ||||||||
| $ | (0.02 | ) | $ | (0.16 | ) | $ | (0.15 | ) | $ | (0.78 | ) | |||||
| Diluted | ||||||||||||||||
| Continuing Operations | $ | (0.02 | ) | $ | (0.22 | ) | $ | (0.15 | ) | $ | (0.82 | ) | ||||
| Discontinued Operations | $ | - | $ | 0.06 | $ | - | $ | 0.04 | ||||||||
| $ | (0.02 | ) | $ | (0.16 | ) | $ | (0.15 | ) | $ | (0.78 | ) | |||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 13,388 | 14,419 | 13,416 | 14,361 | ||||||||||||
| Diluted | 13,388 | 14,419 | 13,416 | 14,361 | ||||||||||||
| Anika Therapeutics, Inc. and Subsidiaries | |||||||
| Consolidated Balance Sheets | |||||||
| (in thousands, except per share data) | |||||||
| (unaudited) | |||||||
| September 30, | December 31, | ||||||
| ASSETS | 2026 | 2025 | |||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 44,957 | $ | 57,481 | |||
| Accounts receivable, net | 24,255 | 23,690 | |||||
| Inventories, net | 30,351 | 18,787 | |||||
| Prepaid expenses and other current assets | 3,482 | 3,400 | |||||
| Total current assets | 103,045 | 103,358 | |||||
| Property and equipment, net | 40,739 | 40,324 | |||||
| Right-of-use assets | 25,775 | 25,939 | |||||
| Other long-term assets | 3,931 | 4,034 | |||||
| Notes receivable | 5,754 | 5,636 | |||||
| Deferred tax assets | 925 | 1,275 | |||||
| Intangible assets, net | 1,650 | 1,650 | |||||
| Goodwill | 7,781 | 8,054 | |||||
| Total assets | $ | 189,600 | $ | 190,270 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 6,033 | $ | 6,041 | |||
| Accrued expenses and other current liabilities | 20,692 | 15,867 | |||||
| Total current liabilities | 26,725 | 21,908 | |||||
| Other long-term liabilities | 733 | 701 | |||||
| Lease liabilities | 24,565 | 24,196 | |||||
| Stockholders’ equity: | |||||||
| Common stock, $0.01 par value | 134 | 139 | |||||
| Additional paid-in-capital | 84,131 | 87,498 | |||||
| Accumulated other comprehensive loss | (5,417 | ) | (4,959 | ) | |||
| Retained earnings | 58,729 | 60,787 | |||||
| Total stockholders’ equity | 137,577 | 143,465 | |||||
| Total liabilities and stockholders’ equity | $ | 189,600 | $ | 190,270 | |||
| Anika Therapeutics, Inc. and Subsidiaries | |||||||
| Consolidated Statements of Cash Flows | |||||||
| (in thousands) | |||||||
| (unaudited) | |||||||
| For the Nine Months Ended September 30, | |||||||
| 2026 | 2025 | ||||||
| Cash flows from operating activities: | |||||||
| Net loss | $ | (2,058 | ) | $ | (11,172 | ) | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||
| Depreciation | 4,351 | 4,054 | |||||
| Amortization of acquisition related intangible assets | - | 357 | |||||
| Non-cash operating lease cost | 1,390 | 1,562 | |||||
| Stock-based compensation expense | 12,718 | 7,626 | |||||
| Deferred income taxes | 329 | 18 | |||||
| Provision for doubtful accounts | (57 | ) | 209 | ||||
| Provision for inventory | 3,190 | 4,969 | |||||
| Interest income on notes receivable | (384 | ) | (424 | ) | |||
| Loss (gain) on sale of assets | 6 | (956 | ) | ||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (645 | ) | 1,953 | ||||
| Inventories | (14,327 | ) | 1,809 | ||||
| Prepaid expenses, other current and long-term assets | (1,386 | ) | 1,016 | ||||
| Accounts payable | (455 | ) | (835 | ) | |||
| Operating lease liabilities | (1,324 | ) | (1,525 | ) | |||
| Accrued expenses, other current and long-term liabilities | 541 | (1,641 | ) | ||||
| Income taxes | 958 | (469 | ) | ||||
| Net cash provided by operating activities | 2,847 | 6,551 | |||||
| Cash flows from investing activities: | |||||||
| Proceeds from sale of Parcus | - | 4,496 | |||||
| Proceeds from sale of intangible assets | - | 600 | |||||
| Notes receivable | 266 | 483 | |||||
| Purchases of property and equipment | (4,541 | ) | (6,178 | ) | |||
| Net cash used in investing activities | (4,275 | ) | (599 | ) | |||
| Cash flows from financing activities: | |||||||
| Proceeds from employee stock purchase plan | 198 | 261 | |||||
| Cash paid for tax withheld on vested restricted stock awards | (1,742 | ) | (1,562 | ) | |||
| Proceeds from exercises of equity awards | 12 | - | |||||
| Repurchases of common stock | (9,543 | ) | (3,971 | ) | |||
| Net cash used in financing activities | (11,075 | ) | (5,272 | ) | |||
| Exchange rate impact on cash | (21 | ) | 151 | ||||
| (Decrease) increase in cash and cash equivalents | (12,524 | ) | 831 | ||||
| Cash and cash equivalents at beginning of period | 57,481 | 57,159 | |||||
| Cash and cash equivalents at end of period | $ | 44,957 | $ | 57,990 | |||
| Anika Therapeutics, Inc. and Subsidiaries | ||||||||||||||||
| Reconciliation of GAAP Income (Loss) from Continued Operations to Adjusted EBITDA | ||||||||||||||||
| (in thousands) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Loss from continuing operations | $ | (311 | ) | $ | (3,175 | ) | $ | (2,058 | ) | $ | (11,780 | ) | ||||
| Interest and other (income) expense, net | (390 | ) | (997 | ) | (1,483 | ) | (1,626 | ) | ||||||||
| Provision for income taxes | (11 | ) | 939 | 295 | 1,709 | |||||||||||
| Depreciation and amortization | 1,439 | 1,403 | 4,351 | 4,263 | ||||||||||||
| Stock-based compensation | 4,244 | 2,215 | 12,718 | 7,758 | ||||||||||||
| Non-recurring professional fees | - | 480 | 169 | 480 | ||||||||||||
| Severance costs | 127 | - | 2,486 | - | ||||||||||||
| Adjusted EBITDA | $ | 5,098 | $ | 865 | $ | 16,478 | $ | 804 | ||||||||
| Anika Therapeutics, Inc. and Subsidiaries | ||||||||||||||||
| Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations | ||||||||||||||||
| (in thousands) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Loss from continuing operations | $ | (311 | ) | $ | (3,175 | ) | $ | (2,058 | ) | $ | (11,780 | ) | ||||
| Stock-based compensation, tax effected | 4,099 | 3,145 | 14,846 | 9,075 | ||||||||||||
| Non-recurring professional fees, tax effected | - | 682 | 197 | 561 | ||||||||||||
| Severance costs, tax effected | 123 | - | 2,902 | - | ||||||||||||
| Adjusted net income (loss) from continuing operations | $ | 3,911 | $ | 652 | $ | 15,887 | $ | (2,144 | ) | |||||||
| Anika Therapeutics, Inc. and Subsidiaries | ||||||||||||||||
Reconciliation of GAAP Diluted Earnings from Continuing Operations Per Share to Adjusted Diluted Earnings from Continuing Opertions Per Share | ||||||||||||||||
| (in thousands, except per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Diluted loss from continuing operations per share | $ | (0.02 | ) | $ | (0.22 | ) | $ | (0.15 | ) | $ | (0.82 | ) | ||||
| Stock-based compensation, tax effected | 0.30 | 0.21 | 1.11 | 0.63 | ||||||||||||
| Non-recurring professional fees, tax effected | - | 0.05 | - | 0.04 | ||||||||||||
| Severance costs, tax effected | 0.01 | - | 0.22 | - | ||||||||||||
| Adjusted diluted income (loss) from continuing operations per share | $ | 0.29 | $ | 0.04 | $ | 1.18 | $ | (0.15 | ) | |||||||
| Anika Therapeutics, Inc. and Subsidiaries | |||||||||||||||||||||||
| Revenue by Channel | |||||||||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||||
| (unaudited) | |||||||||||||||||||||||
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||||||||||
| 2026 | 2025 | $ change | % change | 2026 | 2025 | $ change | % change | ||||||||||||||||
| OEM Channel | $ | 16,601 | $ | 15,844 | $ | 757 | 5 | % | $ | 52,341 | $ | 47,093 | $ | 5,248 | 11 | % | |||||||
| Commercial Channel | 13,993 | 11,973 | 2,020 | 17 | % | 40,475 | 35,111 | 5,364 | 15 | % | |||||||||||||
| $ | 30,594 | $ | 27,817 | $ | 2,777 | 10 | % | $ | 92,816 | $ | 82,204 | $ | 10,612 | 13 | % | ||||||||